

NOTICE

ALTERNATIVE MEDICATION AUTHORIZATION

An Act respecting prescription drug insurance (chapter A-29.01, s. 60.1)

I hereby authorize the temporary use of the following alternative medication:

| | | | | | | | |
|----------|-----------------|--|--------|--|------|--|--|
| 99112194 | <i>Rifampin</i> | | 300 mg | | Caps | | |
|----------|-----------------|--|--------|--|------|--|--|

until the following medications, appearing on the *List of Medications* attached to the *Regulation respecting the List of medications covered by the basic prescription drug insurance plan*, are no longer out of stock:

| | | | | | | | |
|----------|-------------------|------------|--------|-----|------|-------|--------|
| 02092808 | <i>Rifadin</i> | SanofiAven | 300 mg | 100 | Caps | 95.03 | 0.9503 |
| 00343617 | <i>Rofact 300</i> | Valeant | 300 mg | 100 | Caps | 95.03 | 0.9503 |

This notice has effect retroactively from 25 June 2019.

Québec, 5 July 2019

Original signed by:

MARCO THIBAUT
President and Chief Executive Officer
Régie de l'assurance maladie du Québec

Publication of this notice on the website of the Régie de l'assurance maladie du Québec imparts authentic value to it.